Efekt bronchodylatacyjny kombinacji salbutamolu i bromku ipratropium z nebulizatora siateczkowego u dzieci chorych na astmę (doniesienie wstępne) Praca oryginalna
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
wrz 17, 2020
Słowa kluczowe:
astma, dzieci, inhalator siateczkowy, salbutamol, bromek ipratropium
##plugins.themes.bootstrap3.article.main##
Abstrakt
Porównano bronchodylatacyjną odpowiedź oskrzeli po podaniu kombinacji salbutamolu z bromkiem ipratropium vs sam salbutamol inhalowanych z nebulizatora siateczkowego u dzieci w wieku 6–11 lat z cechami klinicznymi i spirometrycznymi zaostrzenia astmy. Wykazano porównywalny efekt bronchodylatacyjny obu terapii w 15. min po podaniu leku.
Pobrania
Dane pobrania nie są jeszcze dostepne
##plugins.themes.bootstrap3.article.details##
Jak cytować
Emeryk , A., Czerwińska-Pawluk , I., Markut-Miotła , E., & Janeczek , K. (2020). Efekt bronchodylatacyjny kombinacji salbutamolu i bromku ipratropium z nebulizatora siateczkowego u dzieci chorych na astmę (doniesienie wstępne) . Alergoprofil, 16(3), 3-9. https://doi.org/10.24292/01.AP.163170920
Numer
Dział
THERAPY
Utwór dostępny jest na licencji Creative Commons Uznanie autorstwa – Użycie niekomercyjne – Bez utworów zależnych 4.0 Międzynarodowe.
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
Bibliografia
1. Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA) Update 2020. https://ginasthma.org/wp-content/uploads/2020/04/GINA-2020-full-report_-final-_wms.pdf (Access: 25.05.2019).
2. Ducharme FM, Sharon DD, Radhakrishnan D et al. Diagnosis and management of asthma in preschoolers: a Canadian Thoracic Society and Canadian Paediatric Society position paper. Can Respir J. 2015; 22: 135-43.
3. Doniec Z, Mastalerz-Migas A, Bręborowicz A et al. Rekomendacje postępowania w astmie wczesnodziecięcej dla lekarzy Podstawowej Opieki Zdrowotnej − KOMPAS POZ. Fam Med Prim Care Review. 2016; 8: 81-92.
4. Graham BL, Steenbruggen I, Miller MR et al. Standardization of Spirometry 2019 Update An Official American Thoracic Society and European Respiratory Society Technical Statement. Am J Respir Crit Care Med. 2019; 200: e70-e88.
5. Hochhaus G, Möllmann H. Pharmacokinetic/pharmacodynamic characteristics of the beta-2-agonists terbutaline, salbutamol and fenoterol. Int J Clin Pharmacol Ther Toxicol. 1992; 30: 342-62.
6. Lawford P, Dowd DE, Palmer KN. A comparison of the duration of action of fenoterol and salbutamol in asthma. Curr Med Res Opin. 1981; 7: 349-51.
7. Scalabrin DM, Solé D, Naspitz CK et al. Efficacy and side effects of beta 2-agonists by inhaled route in acute asthma in children: comparison of salbutamol, terbutaline, and fenoterol. J Asthma. 1996; 33: 407-15.
8. Bremner P, Burgess C, Beasley R et al. Nebulized fenoterol causes greater cardiovascular and hypokalaemic effects than equivalent bronchodilator doses of salbutamol in asthmatics. Respir Med. 1992; 86: 419-23.
9. Bremner P, Siebers R, Crane J et al. Partial vs full beta-receptor agonism. A clinical study of inhaled albuterol and fenoterol. Chest. 1996; 109: 957-62.
10. Bremner P, Burgess CD, Crane J et al. Cardiovascular effects of fenoterol under conditions of hypoxaemia. Thorax. 1992; 47: 814-7.
11. SIGN 158. British Guideline on the Management of Asthma. A national clinical guideline. Revised edition July 2019. www.thoracic.org.uk/Portals/0/Guidelines/AsthmaGuidelines (Access: 3.10.2019).
12. Pollock M, Sinha I, Hartling L et al. Inhaled short-acting bronchodilators for managing emergency childhood asthma: an overview of reviews. Allergy. 2017; 72: 183-200.
13. Qureshi F, Zaritsky A, Lakkis H. Efficacy of nebulized ipratropium in severely asthmatic children. Ann Emerg Med. 1997; 29: 205-11.
14. Griffiths B, Ducharme FM. Combined inhaled anticholinergics and short-acting beta2-agonists for initial treatment of acute asthma in children. Cochrane Database Syst Rev. 2013; (8): CD000060. http://doi.org/10.1002/14651858.CD000060.pub2.
15. Rehder KJ. Adjunct therapies for refractory status asthmaticus in children. Respir Care. 2017; 62: 849-65.
16. Pirożyński M, Florkiewicz E, Sosnowski T. Podstawy nebulizacji – rodzaje inhalatorów. In: Pirożyński M (ed). ABC nebulizacji ze szczególnym uwzględnieniem dawkowania. Via Medica, Gdańsk 2015: 27-42.
17. Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA)Update 2018. https://ginasthma.org/wp-content/uploads/2018/04/wms-GINA-2018-report-tracked_v1.3.pdf (Access: 6.06.2018).
18. www.teva.pl/_itemserver/produkt/pdf_2012/Steri_Neb_Salamol_NEB_PIL_2011_12_21.pdf (Access: 6.06.2018).
19. https://www.mp.pl/pacjent/leki/lek/92844,Iprixon-Neb-roztwor- do-nebulizacji https://www.mp.pl/pacjent/leki/lek/92844,Iprixon-Neb-roztwor- do-nebulizacji (Access: 6.06.2018).
20. Intec Twister Mesh Membrane Inhaler. Operation Manual 2016. – in Polish. https://docplayer.pl/19474476-Inhalator- mesh-instrukcja-obslugi-intec-ne-105.html (Access: 30.05.2020).
21. Pirożyński M, Florkiewicz E, Bodasińki J et al. Calculation of the delivered dose in patients undergoing nebulized asthma therapy. Respir Drug Deliv Europe. 2017; 2: 269-72.
22. Bodasiński J, Emeryk A, Florkiewicz E et al. Nebulizacja: czym, jak, dla kogo, kiedy? Polski Konsensus Nebulizacyjny. Terapia. 2013; nr specjalny: 3-10.
23. Boros P, Franczuk M, Wesołowski S. Zasady interpretacji wyników badania spirometrycznego. Zalecenia Polskiego Towarzystwa Chorób Płuc (dawniej Polskie Towarzystwo Ftyzjopneumonologiczne) dotyczące wykonywania badań spirometrycznych. Pneum Alergol Pol. 2006; 74(suppl 1): 1-23.
24. Fleming S, Thompson M, Stevens R et al. Normal ranges of heart rate and respiratory rate in children from birth to 18 years: a systematic review of observational studies. Lancet. 2011; 377(9770): 1011-8.
25. De Caen AR, Berg MD, Chameides L et al. 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2015; 132: S526-42.
26. Anthracopoulos MB, Karatza AA, Davlouros PA et al. Effects of two nebulization regimens on heart rate variability during acute asthma exacerbations in children. J Asthma. 2005; 42: 273-9.
27. Castro-Rodriguez JA, Rodrigo GJ, Rodríguez-Martínez CE. Principal findings of systematic reviews of acute asthma treatment in childhood. J Asthma. 2015; 52: 1038-45.
28. Coskun S, Yuksel H, Tikiz H et al. Standard dose of inhaled albuterol significantly increases QT dispersion compared to low dose of albuterol plus ipratropium bromide therapy in moderate to severe acute asthma attacks in children. Pediatr Int. 2001; 43: 631-6.
29. Craven D, Kercsmar CM, Myers TR et al. Ipratropium bromide plus nebulized albuterol for the treatment of hospitalized children with acute asthma. J Pediatr. 2001; 138: 51-8.
30. Iramain R, López-Herce J, Coronel J et al. Inhaled salbutamol plus ipratropium in moderate and severe asthma crises in children. J Asthma. 2011; 48: 298-303.
31. Memon BN, Parkash A, Ahmed Khan KM et al. Response to nebulized salbutamol versus combination with ipratropium bromide in children with acute severe asthma. J Pak Med Assoc. 2016; 66: 243-6.
32. Vézina K, Chauhan BF, Ducharme FM. Inhaled anticholinergics and short-acting beta(2)-agonists versus short-acting beta2-agonists alone for children with acute asthma in hospital. Cochrane Database Syst Rev. 2014; (7): CD010283.
33. Louw SJ, Goldin JG, Isaacs S. Relative efficacy of nebulised ipratropium bromide and fenoterol in acute severe asthma. S Afr Med J. 1990; 77(1): 24-6.
34. Watson WT, Becker AB, Simons FE. Comparison of ipratropium solution, fenoterol solution, and their combination administered by nebulizer and face mask to children with acute asthma. J Allergy Clin Immunol. 1988; 82(6): 1012-8.
35. Galindo-Filho VC, Alcoforado L, Rattes C et al. A mesh nebulizer is more effective than jet nebulizer to nebulize bronchodilators during non-invasive ventilation of subjects with COPD: A randomized controlled trial with radiolabeled aerosols. Respir Med. 2019; 153: 60-7.
36. Yang SH, Yang TM, Lin HL et al. Size distribution of salbutamol/ ipratropium aerosols produced by different nebulizers in the absence and presence of heat and humidification. Pulm Pharmacol Ther. 2018; 48: 22-7.
37. Loborec SM, Johnson SE, Keating EA. Financial effect of converting ipratropium-albuterol therapy from inhalers to nebulizer treatments at an academic health system. Am J Health Syst Pharm. 2016; 73(3): 121-5.
38. Lee YH, Kwon GY, Park DY et al. Efficiency of a New Mesh- Type Nebulizer (NE-SM1 NEPLUS) for Intrapulmonary Delivery of Ipratropium Bromide in Surgical Patients. Basic Clin Pharmacol Toxicol. 2016; 118(4): 313-9.
39. Golden LR, DeSimone HA, Yeroshalmi F et al. Severe intraoperative bronchospasm treated with a vibrating-mesh nebulizer. Anesth Prog. 2012; 59(3): 123-6.
40. Murayama N, Murayama K. Comparison of the clinical efficacy of salbutamol with jet and mesh nebulizers in asthmatic children. Pulm Med. 2018; 1648652.
41. Kurosaka F, Nishio H. Comparison of the bronchodilative effects of salbutamol delivered via three mesh nebulizers in children with bronchial asthma. Allergology Int. 2009; 58: 529-35.
42. Kirkland SW, Vandenberghe Ch, Voaklander B et al. Combined inhaled beta‐agonist and anticholinergic agents for emergency management in adults with asthma. Cochrane Database Syst Rev. 2017; 2017(1): CD001284.
43. Jenkins CR, Chow CM, Fisher BL et al. Ipratropium bromide and fenoterol by aerosolized solution. Br J Clin Pharmac. 1982; 14: 113-5.
44. Petrie GR, Palmer KN. Comparison of aerosol ipratropium bromide and salbutamol in chronic bronchitis and asthma. Br Med J. 1975; 5955: 430-2.
45. Thiessen B, Pedersen OF. Maximal expiratory flows and forced vital capacity in normal, asthmatic and bronchitic subjects after salbutamol and ipratropium bromide respiration. Respiration. 1982; 43(4): 304-16.
2. Ducharme FM, Sharon DD, Radhakrishnan D et al. Diagnosis and management of asthma in preschoolers: a Canadian Thoracic Society and Canadian Paediatric Society position paper. Can Respir J. 2015; 22: 135-43.
3. Doniec Z, Mastalerz-Migas A, Bręborowicz A et al. Rekomendacje postępowania w astmie wczesnodziecięcej dla lekarzy Podstawowej Opieki Zdrowotnej − KOMPAS POZ. Fam Med Prim Care Review. 2016; 8: 81-92.
4. Graham BL, Steenbruggen I, Miller MR et al. Standardization of Spirometry 2019 Update An Official American Thoracic Society and European Respiratory Society Technical Statement. Am J Respir Crit Care Med. 2019; 200: e70-e88.
5. Hochhaus G, Möllmann H. Pharmacokinetic/pharmacodynamic characteristics of the beta-2-agonists terbutaline, salbutamol and fenoterol. Int J Clin Pharmacol Ther Toxicol. 1992; 30: 342-62.
6. Lawford P, Dowd DE, Palmer KN. A comparison of the duration of action of fenoterol and salbutamol in asthma. Curr Med Res Opin. 1981; 7: 349-51.
7. Scalabrin DM, Solé D, Naspitz CK et al. Efficacy and side effects of beta 2-agonists by inhaled route in acute asthma in children: comparison of salbutamol, terbutaline, and fenoterol. J Asthma. 1996; 33: 407-15.
8. Bremner P, Burgess C, Beasley R et al. Nebulized fenoterol causes greater cardiovascular and hypokalaemic effects than equivalent bronchodilator doses of salbutamol in asthmatics. Respir Med. 1992; 86: 419-23.
9. Bremner P, Siebers R, Crane J et al. Partial vs full beta-receptor agonism. A clinical study of inhaled albuterol and fenoterol. Chest. 1996; 109: 957-62.
10. Bremner P, Burgess CD, Crane J et al. Cardiovascular effects of fenoterol under conditions of hypoxaemia. Thorax. 1992; 47: 814-7.
11. SIGN 158. British Guideline on the Management of Asthma. A national clinical guideline. Revised edition July 2019. www.thoracic.org.uk/Portals/0/Guidelines/AsthmaGuidelines (Access: 3.10.2019).
12. Pollock M, Sinha I, Hartling L et al. Inhaled short-acting bronchodilators for managing emergency childhood asthma: an overview of reviews. Allergy. 2017; 72: 183-200.
13. Qureshi F, Zaritsky A, Lakkis H. Efficacy of nebulized ipratropium in severely asthmatic children. Ann Emerg Med. 1997; 29: 205-11.
14. Griffiths B, Ducharme FM. Combined inhaled anticholinergics and short-acting beta2-agonists for initial treatment of acute asthma in children. Cochrane Database Syst Rev. 2013; (8): CD000060. http://doi.org/10.1002/14651858.CD000060.pub2.
15. Rehder KJ. Adjunct therapies for refractory status asthmaticus in children. Respir Care. 2017; 62: 849-65.
16. Pirożyński M, Florkiewicz E, Sosnowski T. Podstawy nebulizacji – rodzaje inhalatorów. In: Pirożyński M (ed). ABC nebulizacji ze szczególnym uwzględnieniem dawkowania. Via Medica, Gdańsk 2015: 27-42.
17. Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA)Update 2018. https://ginasthma.org/wp-content/uploads/2018/04/wms-GINA-2018-report-tracked_v1.3.pdf (Access: 6.06.2018).
18. www.teva.pl/_itemserver/produkt/pdf_2012/Steri_Neb_Salamol_NEB_PIL_2011_12_21.pdf (Access: 6.06.2018).
19. https://www.mp.pl/pacjent/leki/lek/92844,Iprixon-Neb-roztwor- do-nebulizacji https://www.mp.pl/pacjent/leki/lek/92844,Iprixon-Neb-roztwor- do-nebulizacji (Access: 6.06.2018).
20. Intec Twister Mesh Membrane Inhaler. Operation Manual 2016. – in Polish. https://docplayer.pl/19474476-Inhalator- mesh-instrukcja-obslugi-intec-ne-105.html (Access: 30.05.2020).
21. Pirożyński M, Florkiewicz E, Bodasińki J et al. Calculation of the delivered dose in patients undergoing nebulized asthma therapy. Respir Drug Deliv Europe. 2017; 2: 269-72.
22. Bodasiński J, Emeryk A, Florkiewicz E et al. Nebulizacja: czym, jak, dla kogo, kiedy? Polski Konsensus Nebulizacyjny. Terapia. 2013; nr specjalny: 3-10.
23. Boros P, Franczuk M, Wesołowski S. Zasady interpretacji wyników badania spirometrycznego. Zalecenia Polskiego Towarzystwa Chorób Płuc (dawniej Polskie Towarzystwo Ftyzjopneumonologiczne) dotyczące wykonywania badań spirometrycznych. Pneum Alergol Pol. 2006; 74(suppl 1): 1-23.
24. Fleming S, Thompson M, Stevens R et al. Normal ranges of heart rate and respiratory rate in children from birth to 18 years: a systematic review of observational studies. Lancet. 2011; 377(9770): 1011-8.
25. De Caen AR, Berg MD, Chameides L et al. 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2015; 132: S526-42.
26. Anthracopoulos MB, Karatza AA, Davlouros PA et al. Effects of two nebulization regimens on heart rate variability during acute asthma exacerbations in children. J Asthma. 2005; 42: 273-9.
27. Castro-Rodriguez JA, Rodrigo GJ, Rodríguez-Martínez CE. Principal findings of systematic reviews of acute asthma treatment in childhood. J Asthma. 2015; 52: 1038-45.
28. Coskun S, Yuksel H, Tikiz H et al. Standard dose of inhaled albuterol significantly increases QT dispersion compared to low dose of albuterol plus ipratropium bromide therapy in moderate to severe acute asthma attacks in children. Pediatr Int. 2001; 43: 631-6.
29. Craven D, Kercsmar CM, Myers TR et al. Ipratropium bromide plus nebulized albuterol for the treatment of hospitalized children with acute asthma. J Pediatr. 2001; 138: 51-8.
30. Iramain R, López-Herce J, Coronel J et al. Inhaled salbutamol plus ipratropium in moderate and severe asthma crises in children. J Asthma. 2011; 48: 298-303.
31. Memon BN, Parkash A, Ahmed Khan KM et al. Response to nebulized salbutamol versus combination with ipratropium bromide in children with acute severe asthma. J Pak Med Assoc. 2016; 66: 243-6.
32. Vézina K, Chauhan BF, Ducharme FM. Inhaled anticholinergics and short-acting beta(2)-agonists versus short-acting beta2-agonists alone for children with acute asthma in hospital. Cochrane Database Syst Rev. 2014; (7): CD010283.
33. Louw SJ, Goldin JG, Isaacs S. Relative efficacy of nebulised ipratropium bromide and fenoterol in acute severe asthma. S Afr Med J. 1990; 77(1): 24-6.
34. Watson WT, Becker AB, Simons FE. Comparison of ipratropium solution, fenoterol solution, and their combination administered by nebulizer and face mask to children with acute asthma. J Allergy Clin Immunol. 1988; 82(6): 1012-8.
35. Galindo-Filho VC, Alcoforado L, Rattes C et al. A mesh nebulizer is more effective than jet nebulizer to nebulize bronchodilators during non-invasive ventilation of subjects with COPD: A randomized controlled trial with radiolabeled aerosols. Respir Med. 2019; 153: 60-7.
36. Yang SH, Yang TM, Lin HL et al. Size distribution of salbutamol/ ipratropium aerosols produced by different nebulizers in the absence and presence of heat and humidification. Pulm Pharmacol Ther. 2018; 48: 22-7.
37. Loborec SM, Johnson SE, Keating EA. Financial effect of converting ipratropium-albuterol therapy from inhalers to nebulizer treatments at an academic health system. Am J Health Syst Pharm. 2016; 73(3): 121-5.
38. Lee YH, Kwon GY, Park DY et al. Efficiency of a New Mesh- Type Nebulizer (NE-SM1 NEPLUS) for Intrapulmonary Delivery of Ipratropium Bromide in Surgical Patients. Basic Clin Pharmacol Toxicol. 2016; 118(4): 313-9.
39. Golden LR, DeSimone HA, Yeroshalmi F et al. Severe intraoperative bronchospasm treated with a vibrating-mesh nebulizer. Anesth Prog. 2012; 59(3): 123-6.
40. Murayama N, Murayama K. Comparison of the clinical efficacy of salbutamol with jet and mesh nebulizers in asthmatic children. Pulm Med. 2018; 1648652.
41. Kurosaka F, Nishio H. Comparison of the bronchodilative effects of salbutamol delivered via three mesh nebulizers in children with bronchial asthma. Allergology Int. 2009; 58: 529-35.
42. Kirkland SW, Vandenberghe Ch, Voaklander B et al. Combined inhaled beta‐agonist and anticholinergic agents for emergency management in adults with asthma. Cochrane Database Syst Rev. 2017; 2017(1): CD001284.
43. Jenkins CR, Chow CM, Fisher BL et al. Ipratropium bromide and fenoterol by aerosolized solution. Br J Clin Pharmac. 1982; 14: 113-5.
44. Petrie GR, Palmer KN. Comparison of aerosol ipratropium bromide and salbutamol in chronic bronchitis and asthma. Br Med J. 1975; 5955: 430-2.
45. Thiessen B, Pedersen OF. Maximal expiratory flows and forced vital capacity in normal, asthmatic and bronchitic subjects after salbutamol and ipratropium bromide respiration. Respiration. 1982; 43(4): 304-16.